Sodium glucose cotransporter-2 (SGLT2) inhibition, an emerging therapeutic option in treatment of diabetes mellitus, have been shown to reduce cardiovascular mortality and preserve kidney function in patients with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.